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Significance Statement
Primary MPGN, including C3 glomerulopathy, is a rare untreatable kidney disease. A minority of 
cases are familial, caused by mutations in complement genes, and non-familial cases have also been 
reported to harbor such mutations. To characterize the genetic architecture of this disease we analyzed 
whole-genome data from 165 PMG cases and 10,250 non-PMG control individuals (146 and 6,442, 
respectively that were unrelated and of European ancestry). We observed no significant enrichment of 
rare variants – in complement genes or exome-wide, but did observe a strong and statistically 
significant common variant association at the HLA locus which was replicated in an independent 
cohort. These findings imply that in most cases the disease is driven by autoimmunity rather than an 
underlying monogenic disorder of complement regulation.
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Significance Statement
Primary MPGN, including C3 glomerulopathy, is a rare untreatable kidney disease. A minority of 
cases are familial, caused by mutations in complement genes, and non-familial cases have also been 
reported to harbor such mutations. To characterize the genetic architecture of this disease we analyzed 
whole-genome data from 165 PMG cases and 10,250 non-PMG control individuals (146 and 6,442, 
respectively that were unrelated and of European ancestry). We observed no significant enrichment of 
rare variants – in complement genes or exome-wide, but did observe a strong and statistically 
significant common variant association at the HLA locus which was replicated in an independent 
cohort. These findings imply that in most cases the disease is driven by autoimmunity rather than an 
underlying monogenic disorder of complement regulation. 
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Abstract
Background: Primary membranoproliferative glomerulonephritis (PMG), including C3 
glomerulopathy (C3G), is a rare, untreatable kidney disease characterized by glomerular complement 
deposition. Familial C3G can be caused by complement gene mutations and rare variants in such genes 
have been reported in non-familial PMG.
Methods: We analyzed whole-genome sequence data from 165 PMG cases and 10,250 non-PMG 
control individuals (146 and 6,442, respectively that were unrelated and of European ancestry) as part 
of the National Institute of Health Research BioResource-Rare Diseases Study. We examined copy 
number, rare and common variants.
Results: We observed no significant enrichment of rare variants in cases in the candidate genes (6.8% 
versus 5.9% in controls, p=0.37) or exome-wide. However, a significant common variant locus was 
identified at 6p21.32 (rs35406322, p=3.29×10-8, OR 1.93) overlapping the HLA locus. Imputation of 
HLA types mapped this signal to a haplotype incorporating DQA1*05:01, DQB1*02:01 and 
DRB1*03:01 (p=1.21×10-8, OR 2.89). This finding was replicated by analysis of HLA serotypes in 338 
individuals with membranoproliferative glomerulonephritis and 15,614 individuals with non-immune 
renal failure (p=1.4×10-4, OR 1.43).
Conclusions: These findings challenge the paradigm of complement gene mutations typically causing 
PMG and implicate an underlying autoimmune mechanism in most cases.
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Introduction
Membranoproliferative glomerulonephritis (MPGN) refers to inflammatory kidney disease in which 
there is increased glomerular mesangial matrix and cellularity, thickening of the capillary walls and 
deposition of immunoglobulins and/or complement. Such appearances can be seen when the immune 
system is chronically activated; the term primary MPGN (PMG) refers to those cases in which an 
underlying infectious, neoplastic or autoimmune disorder is not identified. PMG is divided into immune 
complex PMG (IC-PMG), where there is positive immunostaining for immunoglobulins and 
complement, and C3 glomerulopathy (C3G), where complement C3 is the predominant immunoprotein 
deposited. C3G is subdivided by electron microscopic appearances into C3 glomerulonephritis (C3GN) 
and dense deposit disease (DDD), in which there is characteristic dense transformation of the 
glomerular basement membrane1.
PMG is rare, with incidence estimated at 3-5 per million population2–4. In most cases the cause is not 
known but familial C3G has been linked to genomic rearrangements in the Complement Factor H 
Related genes (CFHR1-5)5–8, bi-allelic loss of function variants of Complement Factor H (CFH)9, and 
an activating mutation of C310. In addition, studies of non-familial cases of PMG have identified rare 
variants in these and other complement genes (previously associated with atypical hemolytic uremic 
syndrome, aHUS) in up to 40% of patients11–14. These findings, together with the almost invariable 
presence of C3 in the glomerulus, have implicated complement alternative pathway activation as a key 
causal mechanism and testing for a complement gene mutations is currently recommended in C3G, 
especially where living related renal transplantation is considered15. 
However, the current paradigm, in which the disease is frequently assumed to result from a rare genetic 
defect of complement regulation, seems incompatible with the following observations: first, the disease 
is usually not familial; second, a C3 nephritic factor (C3NeF), an autoantibody that activates the 
complement alternative pathway in the blood, is detectable in a substantial proportion of patients, 
including those in whom a rare variant in a complement gene is identified11; and third, there is a 
recognized association of MPGN with other autoimmune diseases16–18 including a very substantially 
increased rate of type 1 diabetes mellitus (DM1) in relatives of patients with DDD19. 
Here, we use whole genome sequencing (WGS) to investigate the role of genetic variation in the 
etiology of PMG in the United Kingdom (UK) population, and resolve all three of these anomalous 
observations: while rare genetic variation in the a priori candidate genes was not enriched in PMG (or 
the subset with C3G), there is a strong association with common variation at the HLA locus, explaining 
the phenotypic association with established autoimmune diseases and implicating autoimmunity as the 
key causal mechanism.
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Methods
National Institute for Health Research (NIHR) BioResource Rare Diseases (BR-RD) Study
This study is a part of the NIHR BR-RD Study20 in which WGS has been undertaken on 13,342 
individuals: 12,525 across 16 rare disease domains and 817 apparently healthy subjects (see 
Supplementary Table 2). Given the potential for a shared genetic etiology with PMG, cohorts with 
diseases with a known immunological basis (pulmonary artery hypertension and primary 
immunodeficiencies) and steroid resistant nephrotic syndrome were excluded. Clinical phenotypic data 
for all participants was encoded using Human Phenotype Ontology21, SNOMEDCT and ORPHANET 
codes. Amongst the non-PMG subjects, three participants with the phenotypes microangiopathic 
haemolytic anemia, thrombocytopenia acute kidney injury, or SNOMEDCT or ORPHANET codes 
compatible with hemolytic uremic syndrome, were identified and excluded from the control cohort, as 
were eight subjects with evidence of retinal drusen or macular degeneration.
A summary of the analytic workflow, number of samples analyzed and main findings is provided in 
Fig. S1.
PMG cohort
Recruitment of patients with PMG was undertaken from 10 British pediatric (64 patients) and 18 adult 
centers (120 patients, of whom 21 had pediatric onset of disease). Patients with histologically confirmed 
MPGN either with or without immune-complex deposition (IC-PMG or C3G, respectively) in the 
absence of a known or suspected underlying systemic  cause22 were considered eligible. No genetic pre-
screening was applied. Clinical data were extracted from the UK Rare Renal Disease Registry (RaDaR, 
http://rarerenal.org/radar-registry). Where available, kidney biopsies were reviewed centrally to 
confirm the histological diagnosis and to classify as IC-PMG, C3GN or DDD. Serum C3 nephritic 
factor (C3NeF) and complement C3 and C4 levels were measured using standard clinically validated 
assays.
Whole-genome sequencing - data generation, variant calling, annotation, relatedness and ancestry
The methods employed for data generation and variant calling have been previously described20 and are 
further detailed, along with information on quality control, variant annotation and the identification of 
a subset of unrelated individuals of European ancestry, in the Supplementary Methods.
Structural and copy number variants
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The occurrence of previously described rare SVs and CNVs for PMG5–7,23,24 was examined by manually 
inspecting all SVs and CNVs involving the genes of relevance in unrelated PMG individuals of all 
ethnicity. Subsequent analyses were restricted to the unrelated European cohort of cases and controls. 
A genome-wide comparison of the frequency of deletions per gene between PMG and controls was 
undertaken with p-values calculated by permutation testing (n = 100,000).
Comparison with previously described PMG and aHUS variants
The occurrence of common and rare variants in C3, CD46, CFB, CFH, CFHR1, CFHR3, CFHR5, CFI, 
DGKE, and THBD previously observed in patients with atypical hemolytic uremic syndrome (aHUS), 
age-related macular degeneration (AMD), C3G or thrombotic microangiopathy (TMA), as per the 
Database of Complement Gene Variants (DCGV), a compilation of rare variant data from 3,128 patients 
with aHUS and 443 with C3G tested in six national reference laboratories (http://www.complement-
db.org)14 and a further study11, was examined.
Rare variant candidate gene and exome-wide coding variant burden analysis
Rare coding variants (gnomAD-NFE MAF < 0.0001) of moderate or high impact were extracted. Per-
gene rare variant burden was enumerated as the proportion of individuals (cases versus controls) with 
at least one alternate allele in each gene with significance calculated using the exactCMC function in 
RVTESTS25, which employs a Fisher’s exact test. Analyses were also conducted filtering variants based 
on their predicted deleteriousness using CADD scores26.
Common variant GWAS
Common, high quality variants (MAF ≥ 0.05 in gnomAD-NFE and BR-RD) were retained. Standard 
quality control procedures27 were undertaken (see Supplementary Methods). The final dataset included 
5,897,512 variants with the call rate across the samples exceeding 0.999. GWAS was undertaken with 
PLINK v1.9 assuming additive allele effects using logistic regression with the first five principal 
components as covariates.
HLA imputation
HLA genotyping was performed using BWAKIT/BWAMEM v0.7.15 
(https://github.com/lh3/bwa/tree/master/bwakit) and using HLA-HD v1.2.0.128 (see Supplementary 
Methods). Alleles with a MAF < 0.05 in controls were excluded. Logistic regression with the first five 
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principal components as covariates was performed using PLINK v1.9. Haplotype association analysis 
was performed using PLINK v1.07.
Replication
HLA serotypes from the National Health Service Blood and Transplant (NHSBT) service were utilized 
as an independent replication cohort. The analyzed cohort was a subset of data from all Caucasian 
individuals listed for a kidney transplant in the UK within the last 25 years. HLA serotype data were 
available for HLA-A, HLA-B, HLA-C, HLA-DR and HLA-DQ. Only those serotypes observed at a 
frequency > 0.05 in controls were analyzed for association (n = 28). Chi-square allelic tests and logistic 
regression were performed using PLINK v1.9. Serotypes were converted to molecular subtypes using 
the HLA Dictionary29.
Results
The initial PMG cohort comprised 184 participants. Following centralized biopsy review, 19 were 
excluded, most because the biopsy showed mesangial proliferative glomerulonephritis rather than 
MPGN, leaving 165 (47.9% male). Histological subtypes, complement abnormalities and clinical 
features are summarized in Table 1. Full clinical details for all individuals with C3G (C3GN and DDD) 
are provided in Table S1. A C3NeF was more likely to have been observed in subjects with DDD (Table 
S1), and almost all subjects with a C3NeF or DDD had exhibited a low C3 level on at least one occasion. 
Consistent with previous reports30, transiently low serum C4 was documented in some patients with 
DDD and C3GN but this almost always normalized within weeks of initial presentation30.
The total number of individuals in each BR-RD cohort is shown in Table S2. Excluding PID, PAH and 
SRNS, and control individuals with phenotypic codes compatible with aHUS or AMD (n=11) there 
were 10,250 individuals for use as controls. Of these, 6,491 were unrelated and of European ancestry. 
All the cases were genetically unrelated with the exception of one sibling pair and the majority (n = 
146) were genetically classified as of European ancestry (Fig. S2). Following further quality control 
measures, the final dataset comprised 146 PMG cases and 6,442 non-PMG controls.
In the genes typically screened in patients with C3G and aHUS (namely C3, CD46, CFB, CFH, CFHR5, 
CFI, DGKE and THBD), there was no enrichment of rare (gnomAD-NFE MAF < 0.0001) variants of 
moderate or high predicted impact in the PMG cohort (Fig. 1). The number of individuals with at least 
one such variant was 10 (6.8%, 95% CI 3.5-12.6%) in the PMG cohort, compared with 381 (5.9%, 95% 
CI 5.4-6.5%) in the non-PMG controls (p=0.37, one-tailed Fisher’s exact test), consistent across each 
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of the control cohorts (Fig. S3). Amongst the PMG cohort, there was no difference in the candidate 
gene rare variant burden between the histological subgroups C3GN, DDD, IC-PMG and PMG 
unclassified, between those with or without C3NeF or those with low C3 (Fig. S3). The details of the 
11 and 318 variants identified in the PMG subjects and in non-PMG subjects, respectively, are provided 
in Tables S3 and S4. Analyses were also performed imposing a variable CADD threshold (none to ≥ 
20) and control allele frequency (gnomAD-NFE MAF < 0.0001 to < 0.01); however in none of these 
permutations was there a significant difference between PMG and controls (Fig. S4). Furthermore, there 
was no enrichment of rare variants previously classified as pathogenic or likely pathogenic in the 
DCGV, with one and thirteen such variants identified in PMG and non-PMG individuals, respectively 
(Table S5).
Sixteen previously described common complement gene variants (gnomAD-NFE MAF ≥ 0.05) were 
identified (Table S6). Computing pairwise LD demonstrated that these variants represented 10 
independent signals at r2 < 0.8. Association analysis using logistic regression including principal 
components as covariates identified four variants in the genes C3 and CFH, representing two 
independent signals, that were statistically significant after correction for multiple testing (Bonferroni 
threshold for 10 loci, p<0.005) (Table 2).  The full association statistics for all 16 variants are provided 
in Table S6. There was no evidence of epistasis between the associated variants (p > 0.05).
Across the whole exome, there was no enrichment of rare variants with a moderate or high predicted 
impact per gene in PMG (Fig. S5). The minimum p-value across the exome was 1.9×10-4 as compared 
with the exome-wide significance threshold, correcting for 28,252 genes, of p < 1.77×10-6. The QQ plot 
showed no evidence of deviation from the null (Fig. S6). When filtering the data using a CADD 
threshold of ≥15, the minimum p-value was also 1.9 ×10-4.
The only previously reported rare SV observed in PMG cases was the 6.3 kbp CFHR5 tandem 
duplication (chr1:196950207-196956508) known to cause CFHR5 nephropathy5, present in a single 
individual of Cypriot ancestry. The common CFHR3-CFHR1 deletion was observed at a similar 
frequency in European PMG cases and controls at 0.164 and 0.201, respectively (Fisher’s exact test p 
= 0.139), similar to that in the UK population31. Across all the candidate genes, a total of 65 SVs and 
CNVs were identified of which only one was seen in a PMG case: a 128.3 kbp heterozygous deletion 
involving exon 1 of CFH (chr1:196498350-196626665). Genome-wide, there was no enrichment of 
deletions in PMG cases either in total or per-gene after correcting for multiple testing by permutation 
analysis.
Common variant GWAS examining unrelated individuals of European ancestry, identified one locus 
achieving genome-wide significance (p < 5×10-8) at 6p21.32 (Fig. 2). The genomic inflation (lambda) 
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was 1.017 (QQ plot in Fig. S7). Association statistics for all variants achieving p < 5×10-8 are provided 
in Table S7. At the 6p21.32 locus, the lead variant (rs35406322) was associated at p=3.29×10-8 with 
OR 1.93 (95% CI: 1.53-2.44). Significance was maximal for variants within the gene C6orf10 (Fig. 3). 
The control allele frequency of the lead variant (0.361) approximated to that in gnomAD-NFE (0.376) 
and was consistent across all of the BR-RD control cohorts (Fig. S8). There was no statistically 
significant difference in the frequency of the lead variants by PMG histological subtype, C3NeF status 
or in those with low C3 (Fig. S8). Conditioning on the lead variant abrogated the signal. The second 
lead variant is a known eQTL for multiple genes  in multiple tissue types at genome-wide significance 
including HLA-DRB5, CYP21A1P, C4A and NOTCH4 (Table S8). There was no evidence of epistasis 
(p > 0.05) between the 6p21.32 variants and the nominally associated common candidate complement 
gene variants. Testing dominant and recessive models for the lead variant showed weaker evidence of 
association, suggesting an additive genetic model best explains the association.  A second locus at 
12q14.1 was not statistically significant at the genome-wide level (lead variant rs61938185, p=6.14×10-
8).
Fully imputed HLA genotypes at all six loci were available for all 146 of the PMG cases and 6,386 of 
the controls. A total of 39 HLA alleles were observed with a frequency > 0.05. The strongest association 
was with DQA1*05:01 at p = 2.09×10-8 with OR 1.94 (95% CI 1.54-2.45) followed by DRB1*03:01 
and DQB1*02:01 (Table 3). Full association details for all alleles tested are provided in Table S9. The 
association with both DQB1*02:01 and DRB1*03:01 was abrogated by conditioning on DQA1*05:01. 
The DQA1*05:01|DQB1*02:01|DRB1*03:01 haplotype was observed in cases at a frequency of 0.233 
compared with 0.122 in controls (p = 1.21×10-8, OR 2.19, 95% CI: 1.66-2.89). The control frequency 
of this haplotype approximates to that observed in 1,899 European American individuals (0.131)32. 
These analyses were repeated using HLA types imputed using HLA-HD, yielding similar results (Table 
S9). 
HLA serotypes from the NHSBT were available from 338 individuals with MPGN (both primary and 
secondary) and 15,614 non-MPGN controls with renal failure of non-immune or unknown etiology, the 
largest groups of which were: unknown (n = 6,836), polycystic kidney disease (n = 4,442) and 
pyelonephritis/interstitial nephritis (n = 1,958). Employing a Bonferroni threshold of p < 1.8×10-3 (n = 
28), three serotypes were statistically significantly associated with MPGN with OR of approximately 
1.4: DR17 (corresponding to DRB1*03:01/04), B8 (B*08) and DQ2 (DQB1*02:01/02/03/04/05) (Table 
4). The frequency of the most significant serotype, DR17, was approximately consistent across each of 
the control cohorts, particularly those with larger sample sizes (Fig. S9) and equal to the frequency in 
1,043 UK blood donors33. The significance of B8 and DQ2 was abrogated by conditioning on DR17. 
The DR17|DQ2 haplotype was observed in cases at a frequency of 0.175 compared with 0.129 in 
controls (p = 4.55×10-4, OR 1.43, 95% CI: 1.17-1.75).
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Discussion
In this study we have examined the genetics of PMG using whole-genome sequence data generated 
from a UK-wide collection of cases and a large number of genetic ancestry-matched non-PMG controls. 
The high prevalence of C3NeFs and of reduced serum C3 levels, especially in patients with DDD and/or 
a C3NeF, is consistent with previous literature11,13 and suggests that the cohort under study was 
comparable with previously reported PMG cohorts. While we did observe rare, protein altering variants 
in the candidate genes (encoding components of the complement alternative pathway and other genes 
observed in the related disease aHUS), PMG cases were not enriched for such variants, which occurred 
at a frequency of approximately 7% across all cohorts. Our study of 146 European cases and 6,442 
European controls had >92% power to detect a >15% burden of rare complement gene variants in PMG. 
We also observed association of PMG with common alleles of the candidate complement genes and, 
although not statistically significant at the genome-wide level, this is consistent with previous data and 
provides evidence that variation in genes encoding components of the complement alternative pathway 
affects susceptibility to PMG. 
Power calculation, which we performed before recruitment to this study34, indicated that, using whole 
exome analysis, 100 subjects would have provided >80% power to detect association with rare variants 
in a novel gene accounting for 20% of unexplained cases under a dominant model (power would be 
>95% under a recessive model). We recruited a greater number than this, which suggests that any 
currently unrecognized monogenic disorders are unlikely to account for a significant proportion of PMG 
in the UK population.
Analysis of the frequency of common genetic variants across the genome identified a single locus 
achieving genome-wide significance of p < 5×10-8. Numerous markers at the HLA locus were strongly 
associated with PMG, and imputation identified an associated haplotype containing DQA1*05:01, 
DQB1*02:01 and DRB1*03:01. This finding was replicated in an independent cohort that included both 
primary and secondary MPGN, in which we observed association with the corresponding HLA 
serotypes DQ2 (DQB1*02:01) and DR17 (DRB1*03:01) which are associated with a number of 
immune-mediated disorders. These genes encode components of the MHC class II molecule that are 
found on the surface of antigen presenting cells and are important in initiation of the adaptive immune 
response, including antibody production35. This suggests that a key step in the pathogenesis of these 
disorders is an aberrant adaptive immune response36, which is consistent with the high frequency of 
autoantibodies (i.e. C3NeFs) in these patients. However, the possibility has not been excluded that the 
observed associations are mediated by one of the non-HLA genes spanned by this haplotype, including 
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those encoding complement components C2, Factor B and C4. Variation in dose of C4A and C4B, 
which encode isotypes of C4 that preferentially bind antibody-protein or antibody-cell surface 
complexes respectively37, is known to affect serum C4 activity and has previously been implicated in 
systemic lupus erythematosus (SLE) and schizophrenia38,39. However, direct comparison of the copy 
number of each of these genes showed no significant differences between PMG cases and controls. 
Examining C4NeF levels and the relationship with the observed variants may be informative.
We observed shared genetic risk factors in all the subgroups of PMG (IC-PMG, C3GN and DDD), as 
well as those with and without C3NeF or low C3 (Fig. S5) in this study, implying shared underlying 
disease mechanisms. We did not observe any significant genetic differences between these subgroups 
and it is likely larger studies would be needed to identify such differences, if they exist. Tests for the 
presence of C4 nephritic factors or autoantibodies against complement regulators (which have been 
reported in patients with PMG40) were not available for the whole cohort, so we are unable to determine 
the proportion of patients in whom an autoantibody was present, however the HLA association we 
observed is consistent with other reports in which multiple autoantibodies are detectable in cohorts of 
patients with PMG40 and previous observations showing an association between MPGN/C3G and 
autoimmune disorders 16–1819. The lead variant (e.g. rs3117137) and HLA alleles that we observed to be 
associated with PMG have previously been associated with a number of immune mediated diseases 
including membranous nephropathy41, rheumatoid arthritis42, myasthenia gravis43, asthma44, coeliac 
disease45 and DM146,47, potentially explaining the observed phenotypic association between these 
different disorders. Together, these findings imply that, rather than resulting from a primary genetic 
disorder of complement alternative pathway regulation, in most cases PMG is actually an autoimmune 
disease. 
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Table 1 – Histological categorization and clinical details. Ultrastructural and immunostaining data to 
allow sub-classification into IC-PMG, C3GN or DDD were available for 114 subjects. Results of 
clinically accredited C3NeF assays were available for 67 and serum C3 and C4 levels were available 
for 71 subjects, but only a small number of those with end stage renal disease.
Category Total (%)
C3NeF detected 
(% of 69)
Low C3 (<0.68 
g/L) (%)
Low C4 (<0.18 
g/L) (%)
All subjects 165 (100) 25 (36.2) 58 (69.0) 38 (45.2)
IC-PMG 53 (46.5) 6 (24.0) 19 (63.3) 19 (63.3)
C3GN 39 (34.2) 8 (33.3) 19 (67.9) 8 (28.6)
DDD 22 (19.3) 10 (58.8) 16 (84.2) 9 (47.4)
Pediatric onset 85 (51.5) 23 (40.4) 51 (77.2) 33 (50.0)
Immunosuppression 75 (56.0) 18 (38.3) 42 (77.8) 27 (50.0)
End stage renal disease 42 (25.4) 5 (41.7) 6 (42.9) 1 (7.1)
Renal transplant 30 (18.2) 4 (57.1) 4 (44.4) 0 (0.0)
C3NeF detected 25 (36.2) - 23 (92.0) 11 (44.0)
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Table 2 - Association statistics comparing PMG with controls for four common variants in complement genes previously described at altered frequency in 
individuals with aHUS/MPGN. gnomAD-NFE: allele frequency in non-Finish Europeans in the gnomAD database. Positions shown are for Build 37 of the 
human genome. The two chromosome 19 variants and two chromosome 1 variants are in linkage disequilibrium (r2 = 0.844 and r2 = 0.999, respectively).
Chr Pos Ref Alt rsID Gene HUGO 
Effect
Case Control gnomAD-
NFE
OR
(95% CI)
P
1 196654324 A C rs1061147 CFH p.A307A 0.534 0.620 0.617 0.71 (0.56-0.89) 3.5×10-3
1 196659237 C T rs1061170 CFH p.H402Y 0.534 0.620 0.616 0.71 (0.56-0.89) 3.4×10-3
19 6713262 G A rs1047286 C3 p.P314L 0.284 0.213 0.200 1.47 (1.13-1.90) 3.9×10-3
19 6718387 G C rs2230199 C3 p.R102G 0.295 0.218 0.206 1.49 (1.16-1.93 2.1×10-3
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Table 3 - Association statistics comparing PMG and controls for the three most significant HLA alleles 
imputed using BWAKIT/BWAMEM.
Allele Case Control OR (95% CI) P
DQA1*05:01 0.291 0.154 1.94 (1.54-2.45) 2.09×10-8
DRB1*03:01 0.264 0.146 1.94 (1.51-2.50) 2.46×10-7
DQB1*02:01 0.264 0.144 1.81 (1.43-2.29) 7.69×10-7
Table 4 - Association statistics for the HLA serotypes associated with MPGN in the NHSBT data after 
correcting for multiple testing (p < 1.8×10-3).
Serotype Case Control OR (95% CI) P
DR17 0.188 0.137 1.46 (1.20-1.78) 1.4×10-4
B8 0.186 0.140 1.42 (1.16-1.72) 4.7×10-4
DQ2 0.283 0.228 1.33 (1.12-1.58) 9.3×10-4
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Figures
Fig. 1
Burden of rare variants with moderate or high predicted impact in candidate genes 
comparing unrelated European PMG (n = 146) with controls (n = 6,442). Vertical 
dotted lines indicate the 95% confidence intervals.
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Fig. 2
GWAS Manhattan plot comparing European unrelated PMG cases (n = 146) and controls (n = 
6,442). One locus surpasses the genome-wide significance threshold (p < 5×10-8, indicated by the 
red line) on chromosomes six.
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Fig. 3
LocusZoom plot for the chromosome 6 locus associated with PMG at genome-wide 
significance with variants colored based on their linkage disequilibrium (LD) using 1000 
Genomes (November 2014) European data. As there were no reference LD data available for 
the lead marker, the second most significant marker was used (chr6:32313531, rs3117135). 
A horizontal red dotted line indicates p=5×10-8.
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2 Supplementary Methods
National Institute for Health Research (NIHR) BioResource Rare
Diseases (BR-RD) Study
In addition to primary membranoproliferative glomerulonephritis (PMG), the pheno-
types examined include: bleeding/thrombotic/platelet disorders (BPD)[1], cerebral small
vessel disease (CSVD), Ehlers-Danlos syndrome (EDS), hypertrophic cardiomyopathy
(HCM), intrahepatic cholestasis of pregnancy (ICP), Leber Hereditary Optic Neuropa-
thy (LHON), multiple primary malignant tumors (MPMT)[2], pulmonary arterial hy-
pertension (PAH)[3], [4], primary immune disorders (PID)[5], inherited retinal disorders
(IRD)[6], [7], neurological and developmental disorders (NDD), neuropathic pain dis-
orders (NPD), stem cell and myeloid disorders (SMD) and steroid resistant nephrotic
syndrome. Data were also generated from process controls (CNTRL), individuals with
one of 162 rare diseases with no known causal mutation by standard of care genetic test-
ing (GEL) and from healthy individuals from the UK Biobank[8] with extreme red blood
cell traits (UKBio). A breakdown of the number of individuals per cohort can be found
in Table S2.
Ethics
Written informed consent was provided by all participants. The study was approved by
the East of England Cambridge South National Research Ethics Committee (Reference
13/EE/0325) and the South West Central Bristol Research Ethics Committee (Reference
10/H0106/8).
Whole-genome sequencing - data generation, variant calling and
annotation
In brief, DNA was extracted from whole blood, underwent initial quality control assess-
ment and was prepared using the Illumina TruSeq DNA PCR-Free sample preparation kit
(Illumina, Inc.). Subsequently 100-150 base pair paired-end sequencing was undertaken
using an Illumina HiSeq 2500 or HiSeq X. The minimum coverage required per sample
was at least 95% of the autosomal genome at 15 times read depth. Reads were aligned
against the human genome (GRCh37) using Isaac (Illumina)[9].
Single nucleotide variants (SNVs) and indels were called using the Illumina Starling soft-
ware. Sample duplicates (n = 136) and those with poor data quality (n = 14) were
excluded. SNVs and indels were normalized and combined into gVCFs. For each vari-
ant, the overall pass rate (OPR) was enumerated as the product of the pass rate (the
proportion of alternate genotype passing the original variant filtering) and the call rate
(proportion of non-missing genotypes). A genotype quality (GQ) threshold of 20 and
depth (DP) threshold of 10 were imposed per genotype per individual; calls failing to
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meet either of these criteria were set to missing. Only variants with OPR ≥ 0.8 and
frequency of missingness ≤ 0.01 were retained.
Variants were annotated using the Ensembl Variant Effect Predictor (v89)[10], their pre-
dicted deleteriousness based on CADD score[11] and their frequency in gnomAD (http://
gnomad.broadinstitute.org/variant)[12]. Variants were filtered using bcftools (v1.8)[13]
and further filtered and analyzed using custom scripts written in Python and R.
Relatedness and ancestry
A subset of high quality common variants was extracted for ancestry and relatedness
estimation in the full BR-RD dataset. These variants were selected as they were present
on three Illumina genotyping arrays (HumanOmni2.58v1.1, HumanCoreExome-12v1.1
and HumanCoreExome-24v1.0), were biallelic, were genotyped in all BR-RD individuals,
had a minor allele frequency (MAF) ≥ 0.3, were not in linkage disequilibrium (LD)
(pruned using PLINK v1.9[14] with r2 < 0.2) and had OPR ≥ 0.99. An initial kinship
matrix was computed using KING[15]. Subsequently, PC-AiR[16] and PC-Relate[17]
in the R package GENESIS were utilized to correct the kinship matrix for population
structure. The resulting kinship matrix was used as input in PRIMUS[18] to identify the
maximal set of unrelated individuals. The ancestry of all BR-RD samples was ascertained
by calculating principal components (PC) using unrelated 1000 Genomes individuals[19]
and projecting the BR-RD genotypes onto this vector space. A multivariate model was
then used to classify each subject as being either of non-Finnish European, Finnish,
African, South Asian and East Asian based on the 1000 Genomes data.
Further quality control
As described below in the section entitled ‘Common variant GWAS’, per individual het-
erozygosity and missingness were computed using common variants and individuals with
values greater than three standard deviations from the mean for each parameter were
excluded (n = 49). This resulted in a final dataset comprising 146 PMG cases and 6,442
non-PMG controls that was used for all subsequent analyses (see Table S2).
Structural variants
Structural variants (SVs) and copy number variants (CNVs) were called using Manta[20]
and Canvas[21], respectively. Variants were categorized as CNV gain/loss, translocations,
deletions, tandem duplications and insertions. Only those variants within at least 10
base pairs of an exon were included. Known common benign variants[22] and those
failing Illumina quality filters were excluded. Variants were filtered based on their allele
frequency in all BR-RD samples excluding those at > 0.001. Deletions identified by
both Canvas and Manta with a 20% minimum overlap were identified. The genome-
wide comparison of the frequency of deletions per gene between cases and controls was
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undertaken using those deletions identified by both Canvas and Manta using PLINK
v1.07[23].
Comparison with previously described PMG and aHUS variants
Details on 843 common and rare variants within the genes C3, CD46, CFB, CFH, CFHR1,
CFHR3, CFHR5, CFI, DGKE, and THBD previously observed in patients with atypi-
cal hemolytic uremic syndrome (aHUS), age-related macular degeneration (AMD), C3G
or thrombotic microangiopathy (TMA) were extracted from the Database of Comple-
ment Gene Variants (DCGV) (http://www.complement-db.org)[24]. The variants were
manually curated to remove duplicates leaving 830. Three additional common variants
previously studied in MPGN but missing from the database were added[25]. Observed
sequence variants were matched to these previously described variants based on either
overlapping (i) genomic position, reference and alternate alleles, (ii) Human Genome
Variation Society (HGVS)[26] protein effect or (iii) HGVS cDNA effect. For common
variants (gnomAD non-Finnish Europeans (gnomAD-NFE) MAF ≥ 0.05)), logistic re-
gression association analysis with five principal components as covariates, and epistasis
analyses were performed using PLINK v1.9.
Rare variant candidate gene and genome-wide coding variant
burden analysis
To extract coding variants, exon positions as defined by both Ensembl[27] and RefSeq[28]
were utilized. Variants residing within these loci passing quality control were retained.
Only data from European unrelated PMG and controls were examined. Variants equal to
or exceeding an allele frequency of 0.0001 in gnomAD-NFE were excluded. Only variants
of moderate (inframe indels and missense variants) or high (splice acceptor/donor, stop
gain/loss, start loss, frameshift) impact were analyzed. Per-gene rare variant burden
was enumerated as the proportion of individuals (cases versus controls) with at least one
alternate allele in each gene with significance calculated using the exactCMC function
in RVTESTS[29], which employs a Fisher’s exact test. A Manhattan plot was produced
using the R package qqman[30]. A QQ plot including 95% confidence intervals was
produced using the R packge snpStats. As per the method employed by qqman, only
p-values < 1 have been included in the QQ plot.
Common variant GWAS
Variants passing quality control filters that had a MAF > 0.05 in gnomAD-NFE and
across all samples in BR-RD were retained (n = 5,939,292). Standard quality control
procedures[31] were subsequently employed to remove samples and variants of poor qual-
ity. Initially, heterozygosity and per-sample missingness were computed using PLINK
v1.9. Individuals with heterozygosity or missingness greater than three standard devia-
tions from the mean were excluded. This resulted in the exclusion of 66 individuals (none
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with PMG). Next, the data were filtered to remove variants demonstrating deviation from
Hardy-Weinberg equilibrium at p < 0.001 and those at a MAF < 0.05 in controls. GWAS
was undertaken with PLINK v1.9 assuming additive allele effects using logistic regres-
sion with the first five principal components as covariates. Following completion of the
GWAS, a Manhattan plot was produced using the R package qqman[30]. A QQ plot
including 95% confidence intervals was produced using the R packge snpStats. High res-
olution plots showing the LD between markers (as per 1000 Genomes November 2014
European data) were generated using LocusZoom[32]. eQTL data were extracted from
the Genotype-Tissue Expression (GTEx) project (https://www.gtexportal.org)[33].
HLA imputation
HLA genotyping was performed by realignment of the raw sequence data to HLA contigs
using BWAKIT / BWAMEM v0.7.15 (https://github.com/lh3/bwa/tree/master/
bwakit). HLA alleles A, B, C, DQA1, DQB1 and DRB1 were examined. For each
allele, only the most likely genotypes were carried forward.
HLA genotyping was also performed using HLA-HD v1.2.0.1[34] which maps the raw
sequence data to an extensive dictionary of HLA alleles. This was run using default
parameters. HLA alleles A, B, C, DQA1, DQB1, DRB1-9, DPA1, DMA, DMB, DOA,
DOB, DRA, E, F, G, H, J, K, L and V were imputed.
The imputed results generated by the two methods were processed separately. The results
were converted to PED/MAP format at four-digit resolution and filtered on missingness
per individual (99%) and per variant (99%).
3 Supplementary Results
HLA replication
Identical serotypes at all five HLA types tested were observed for seven (2.1%) of the
cases and 1106 (7.1%) of the controls. The coverage of the observed serotypes for each of
the five HLA types were as follows: A 99.5%, B 99.5%, C 87.6%, DR 99.5%, DQ 92.8%.
Of the European PMG individuals in the discovery analysis, 22 had undergone renal
transplantation and might have been included within the MPGN NHSBT data. Amongst
these cases, four and two individuals were heterozygous and homozygous, respectively,
for DRB1*03:01 (corresponding to DR17). Removing four heterozygous, two homozygous
and sixteen wild type cases from the MPGN DR17 analysis, this serotype remained sig-
nificantly associated with disease (p = 2.0× 10−4), confirming independent replication.
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Figure S1: Sample and analytic workflow for both the discovery and replication compo-
nents of the study. The flowchart shows the number of samples included, the analytical
strategies employed and the main findings.
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Figure S2: Principal component analysis showing the first four principal components
highlighting PMG cases (red) and controls (black) by ethnicity (European circle, not
European cross). All unrelated individuals post-exclusions, pre-common variant quality
control have been plotted.
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Figure S4: Cumulative burden of rare variants with moderate or high predicted impact
in the PMG candidate genes with variable CADD threshold (none to ≥ 20) and control
allele frequency (gnomAD-NFE MAF < 0.0001 to < 0.01), in PMG and control subjects.
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Figure S5: Exome-wide rare variant burden analysis Manhattan plot comparing European
unrelated PMG cases and controls. No gene surpasses the exome-wide Bonferroni signif-
icance threshold indicated by a horizontal red line (p < 1.77× 10−6). Genes achieving p
< 1× 10−3 have been annotated.
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Figure S6: QQ plot for exome-wide rare variant gene burden analysis. The ob-
served/expected chi-square values and corresponding p-values are shown. The grey
shaded area indicates the 95% confidence interval of the null.
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Figure S7: QQ plot for the common variant genome-wide association analysis. The
observed/expected chi-square values and corresponding p-values are shown. The grey
shaded area indicates the 95% confidence interval of the null. The genomic inflation
(lambda) is 1.017.
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Figure S8: Allele frequency of the lead variant from the chromosome 6 locus in each of
the control cohorts of BR-RD separately (black), together (blue), in PMG (red) and the
subphenotypes of PMG based on histopathology (C3GN, DDD, IC-MPGN, PMG un-
classified), C3NeF status (positive/negative) and those with low C3 (purple). Horizontal
lines indicate the 95% confidence intervals.
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Figure S9: Frequency of HLA serotype DR17 in the NHSBT data showing the controls
utilized separately, together (blue) and MPGN (red). Horizontal lines indicate the 95%
confidence intervals.
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6 Supplementary Tables
See separate Excel Spreadsheet.
Table S1
Full histological categorization and clinical details for all subjects with C3G (C3GN and
DDD). In the Source of histology data column, the abbreviations used are as follows:
LM light microscopy, EM electron microscopy and IS immunostain. ESRD is end-stage
renal disease.
Table S2
Number of individuals in each of the BR-RD cohorts at each stage of filtering.
Table S3
Prioritized rare moderate/high impact variants identified in candidate genes in PMG
subjects. Chr (chromosome), Pos (position), Ref (reference allele) and Alt (alternate
alele) are given with reference to Build 37 of the human genome. HGVSc and HGVSp
effects are given for the Ensembl transcript that is canonical or otherwise the transcript
with the highest impact variant effect. gnomAD AF NFE is the frequency of the
variant in non-Finish European individuals in gnomAD. gnomAD AF is the frequency
of the variant in all gnomAD cohorts. Phenotype is the histological subphenotype
(PMG is PMG unclassified). AC Controls gives the number of non-PMG individuals
with each variant. Controls Cohort AC shows the non-PMG cohorts in which subjects
with each variant are identified.
Table S4
Prioritized rare moderate/high impact variants identified in candidate genes in non-PMG
subjects. The column definitions (where they overlap) are as per Table S3.
Table S5
Rare variants in candidate genes previously classified as pathogenic or likely pathogenic in
the Database of Complement Gene Variants (DCGV). DCGV cDNA and DCGV Protein
are the cDNA and protein effects of the variant as reported in DCGV. DCGV Conditions
gives the diseases each variant has been previously identified in. DCGV Path is the
pathogenicity classification of the variant as per DCGV (using American College of Med-
ical Genetics and Genomics and the Association for Molecular Pathology criteria, see
DCGV publication by Osborne et al.). AC gives the number of individuals with each
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variant. Further column definitions (where they overlap) are as per Table S3. A single
variant seen in a PMG case is shown in red.
Table S6
Association statistics for sixteen common variants in candidate genes previously identified
in association with aHUS or MPGN comparing PMG with controls. Linkage disequilib-
rium, as calculated from the data itself, enable identification of independent signals, as
shown with r2. A1 is the minor allele. HUGO Effect gives the effect of the variant as
described in the Database of Complement Gene Variants (DCGV). F A and F U give
the frequency of the minor allele (A1) in PMG cases and controls, respectively. OR, L95
and U95 give the odds ratio and 95% confidence intervals. P is the p-value as calculated
using logistic regression with five principal components as covariates. Further column
definitions (where they overlap) are as per Table S3. P-values achieving significance after
correcting for multiple testing are shown in red.
Table S7
Association statistics for all variants achieving p < 5× 10−8 in the genome-wide associ-
ation study. The column definitions (where they overlap) are as per Table S6.
Table S8
GTEx eQTL results for rs3117135 (https://gtexportal.org/home/snp/rs3117135).
NES is the normalized effect size.
Table S9
Association statistics for imputed HLA alleles using BWAKIT/BWAMEM and HLA-HD.
For each HLA allele, for each imputation method (BWAKIT/BWAMEM (BWA-) and
HLA-HD (HLAHD-)) the frequency in PMG ( A), controls ( U), odds ratio (OR),
confidence intervals (lower L95 and upper U95) and p-value (P) are shown.
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